A practical reference on mitochondrial biogenesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-25. Anything still debated is marked as such rather than presented as settled.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
In Switzerland, a maximum radiation exposure of 1 mSv per year and a maximum of 5 mSv per year for the patient's relatives may not be exceeded. After discharge following radioiodine therapy, a maximum dose rate of 5 μSv per hour at a distance of 1 meter is permitted, which corresponds to a residual activity of approximately 150 MBq. In the event of early discharge, the supervisory authority must be notified up to a dose rate of 17.5 μSv/h; above 17.5 μSv/h, permission must be obtained. If the patient is transferred to another ward, the responsible radiation protection officer must ensure that appropriate radiation protection measures are taken there, e.g. that a temporary control area is set up.
This one is to be put on first, is also worn overnight, and exerts a basic pressure of 20 mmHg or less. Also, it keeps the wound dressing in place. A second stocking, often brown, sometimes black, achieves a pressure of 20–30 mmHg and is applied over the other stocking during the daytime. Intermittent pneumatic compression devices may be used, but it is not clear that they are superior to simple compression dressings. It is not clear if interventions that aim to help people adhere to compression therapy are effective. More research is needed in this field.
Kenney, Padraic. 1989: Democratic Revolutions at the Cold War's End: A Brief History with Documents (2009) covers Poland, the Philippines, Chile, South Africa, Ukraine, and China Leffler, Melvyn P. For the Soul of Mankind: The United States, the Soviet Union, and the Cold War (2007) pp 338–450. Mann, James. The Rebellion of Ronald Reagan: A History of the End of the Cold War (2010). popular Matlock, Jack F. Autopsy on an Empire (1995) online by US ambassador to Moscow Matlock, Jack F. Reagan and Gorbachev : how the Cold War ended (2004) online Powaski, Ronald E. The Cold War: The United States and the Soviet Union, 1917–1991 (1998) Romero, Federico. "Cold War historiography at the crossroads." Cold War History 14.4 (2014): 685–703. online Shultz, George P. Turmoil and Triumph: My Years as Secretary of State (1993), a primary source Wilson, James Graham. The Triumph of Improvisation: Gorbachev's Adaptability, Reagan's Engagement, and the End of the Cold War (2014) Wohlforth, William C. "Realism and the End of the Cold War." International Security 19.3 (1994): 91–129. online Zubok, Vladislav M. "Gorbachev and the End of the Cold War: Perspectives on History and Personality," Cold War History (2002) 2:2, 61–100, DOI: 10.1080/713999954 Zubok, Vladislav M. A failed empire: the Soviet Union in the Cold War from Stalin to Gorbachev (2009). online Archived 2020-09-19 at the Wayback Machine
Louisiana governor Jeff Landry requested the deployment of the National Guard for large upcoming events: the Bayou Classic college football event November 27–29, New Year Eve and Day celebrations, and Mardi Gras celebrations in February. The New Orleans police superintendent said, "We are working together and planning their deployment." New Orleans had been the site of the January 1, 2025, terrorism attack in which 14 persons lost their lives and at least 57 persons were injured.
In October 2025, GSK announced it had acquired the rights to a prostate cancer drug developed by Syndivia, a French biotechnology company, for £268 million. In January 2026, GSK agreed to acquire Rapt Therapeutics in a deal valued at $2.2 billion. In January 2026, Alteogen Inc. entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK, allowing Tesaro to acquire world-wide rights to use ALT-B4, Alteogen's novel hyaluronidase utilising Hybrozyme technology, for the development and commercialisation of a subcutaneous formulation of dostarlimab, a programmed death receptor-1 (PD-1) blocking antibody. In February 2026, GlaxoSmithKline announced an agreement to acquire Canada-based biopharmaceutical firm 35Pharma for $950 million in cash. The deal includes the early-stage drug HS235 for pulmonary arterial hypertension and related conditions. In June 2026, GSK announced it was acquiring Nuvalent, an American biopharmaceutical company, for $10.6 billion. Subject to regulatory and shareholder approval, if complete, the deal will be its largest in more than 10 years.
Sources: en.wikipedia.org
== Personalized Medicine == As metabolite analyses are being conducted at the individual patient level, pharmacometabolomics may be considered a form of personalized medicine. This field is currently being employed in a predictive manner to determine the potential responses of therapeutic compounds in individual patients, allowing for more customized treatment regimens. It is anticipated that such pharmacometabolomics approaches will lead to the improved ability to predict an individual's response to a compound, the efficacy and metabolism of it as well as adverse or off-target effects that may take place in the body. The metabolism of certain drugs varies from patient to patient as the copy number of the genes which code for common drug metabolizing enzymes varies within the population, and leads to differences in the ability of an individual to metabolize different compounds. Other important personal factors contributing to an individual's metabolic profile, such as patient nutritional status, commensal bacteria, age, and pre-existing medical conditions, are also reflected in metabolite assessment., Overall, pharmacometabolomic analyses combined with such approaches as pharmacogenetics, can function to identify the metabolic processes and particular genetic alterations that may compromise the anticipated efficacy of a drug in a particular patient. The results of such analyses can then allow modification of treatment regimens for an optimal outcome.
=== 2025–present === In February 2026, before an upcoming US–Brazil meeting, the Brazilian president Luiz Inácio Lula da Silva told a news conference in New Delhi that Brazil wants neither "a new Cold War" nor any country's intervention but rather be "treated equally" like all other countries. He declared this a message to the second administration of Donald Trump, who became the US president again in 2025, succeeding Biden.
==== Season 1 ==== At the beginning of the series, the Roys gather to celebrate Logan's 80th birthday, where it is assumed he will step down as CEO and name Kendall as his successor. However, he shocks his family when he announces he will stay on as CEO and hands them documents naming Marcia as his chief trustee upon his death. Logan suffers a debilitating stroke later that day and is admitted to the hospital, where the rest of his family and inner circle debate how to steward the company while he is incapacitated. Logan soon recovers and announces at a gala event that he will remain CEO, but continues displaying erratic behavior. Kendall plots a vote of no confidence against his father along with Roman and several members of the company's senior management, but it ultimately fails, in part because Logan refuses to leave the room during the vote and instead berates several board members into siding with him, while firing everyone who voted for the motion (including Kendall). Over the following months, Logan remains at odds with his children: Shiv goes to work as a political consultant for presidential candidate Gil Eavis, a Democratic Senator who despises Logan and Waystar, while Kendall - a recovering addict - relapses and derails a family therapy session intended to allay public concerns over the company's stability. At Shiv's wedding, Logan learns that Kendall has plotted a hostile takeover of the company alongside his friend Stewy and Logan's nemesis Sandy Furness.
Yohimbine, also known as quebrachine, is an indole alkaloid derived from the bark of the African tree Pausinystalia johimbe (yohimbe) and from the bark of the unrelated South American tree Aspidosperma quebracho-blanco. It is a veterinary drug used to reverse xylazine. Substances purported to be extracts from the yohimbe tree have been marketed as dietary supplements for various purposes, especially for erectile dysfunction, but they contain highly variable amounts of yohimbine, if any; no published clinical evidence supports their efficacy for treating sexual dysfunction or any disease. In the United States, it is illegal to market an over-the-counter (OTC) supplement product containing yohimbine as a treatment for any supposed health effect without having approval from the Food and Drug Administration (FDA). In the United Kingdom, yohimbine is an unlicensed drug, rarely and specifically compounded as a "prescription-only medicine", while yohimbine herbal supplements are banned from manufacturing as dangerous substances.
Sources: en.wikipedia.org
Hemoglobin C/ beta thalassemia: common in Mediterranean and African populations generally results in a moderate form of anemia with splenomegaly. Hemoglobin D/ beta thalassemia: common in the northwestern parts of India and Pakistan (Punjab region). Hemoglobin E/ beta thalassemia: common in Cambodia, Thailand, and parts of India, it is clinically similar to β thalassemia major or β thalassemia intermedia. Hemoglobin S/ beta thalassemia: common in African and Mediterranean populations, it is clinically similar to sickle-cell anemia. Delta-beta thalassemia is a rare form of thalassemia in which there is a reduced production of both the delta and beta globins. It is generally asymptomatic. There are two clinically significant combinations involving the sickle cell gene:
=== Detection in body fluids === DMT may be measured in blood, plasma or urine using chromatographic techniques as a diagnostic tool in clinical poisoning situations or to aid in the medicolegal investigation of suspicious deaths. In general, blood or plasma DMT levels in recreational users of the drug are in the 10–30 μg/L range during the first several hours post-ingestion. Less than 0.1% of an oral dose is eliminated unchanged in the 24-hour urine of humans.
With the return of Oak Miller and a string of dangerous outsiders, the supposedly sleepy town becomes at times a lawless place, and Wise must take on the criminal underworld to restore the peaceful retreat he hoped for.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.